GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyprotex PLC (LSE:CRX) » Definitions » Price-to-Free-Cash-Flow

Cyprotex (LSE:CRX) Price-to-Free-Cash-Flow : 12.88 (As of May. 14, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Cyprotex Price-to-Free-Cash-Flow?

As of today (2024-05-14), Cyprotex's share price is £1.61. Cyprotex's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2016 was £0.13. Hence, Cyprotex's Price-to-Free-Cash-Flow Ratio for today is 12.88.

The historical rank and industry rank for Cyprotex's Price-to-Free-Cash-Flow or its related term are showing as below:

LSE:CRX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 32.23
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Cyprotex's Free Cash Flow per Share for the six months ended in Jun. 2016 was £0.06. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was £0.13.


Cyprotex Price-to-Free-Cash-Flow Historical Data

The historical data trend for Cyprotex's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyprotex Price-to-Free-Cash-Flow Chart

Cyprotex Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.33 38.00 47.50 - 10.08

Cyprotex Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 10.08 -

Competitive Comparison of Cyprotex's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Cyprotex's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyprotex's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyprotex's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cyprotex's Price-to-Free-Cash-Flow falls into.



Cyprotex Price-to-Free-Cash-Flow Calculation

Cyprotex's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.61/0.125
=12.88

Cyprotex's Share Price of today is £1.61.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyprotex's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2016 was £0.13.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Cyprotex  (LSE:CRX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Cyprotex Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cyprotex's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyprotex (LSE:CRX) Business Description

Traded in Other Exchanges
N/A
Address
Cyprotex PLC was incorporated on October 25, 2001. The Company together with its subsidiaries, provides in vitro and in silico ADMET and PK (absorption, distribution, metabolism, excretion, toxicity and pharmacokinetics) information to a number of different industries including the Pharmaceutical, Biotechnology, Cosmetic, Personal Care, Agrochemical, Chemical Industries and Academia. It provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. The Company operates in North America, Mainland Europe and United Kingdom.

Cyprotex (LSE:CRX) Headlines

No Headlines